151 related articles for article (PubMed ID: 8783664)
1. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results.
Paine GD; Taylor CW; Lopez MH; Johnson CS; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):35-9. PubMed ID: 8783664
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.
Hu L; Hofmann J; Holash J; Yancopoulos GD; Sood AK; Jaffe RB
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6966-71. PubMed ID: 16203789
[TBL] [Abstract][Full Text] [Related]
4. Effects of IL-12 on human ovarian tumors engrafted into SCID mice.
Silver DF; Hempling RE; Piver MS; Repasky EA
Gynecol Oncol; 1999 Feb; 72(2):154-60. PubMed ID: 10021294
[TBL] [Abstract][Full Text] [Related]
5. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: A possible oxygen effect.
Silver DF; Piver MS
Gynecol Oncol; 1999 May; 73(2):280-4. PubMed ID: 10329047
[TBL] [Abstract][Full Text] [Related]
6. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Taylor CW; Wang LM; List AF; Fernandes D; Paine-Murrieta GD; Johnson CS; Capizzi RL
Eur J Cancer; 1997 Sep; 33(10):1693-8. PubMed ID: 9389935
[TBL] [Abstract][Full Text] [Related]
7. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts.
Bao R; Selvakumaran M; Hamilton TC
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):373-9. PubMed ID: 10985897
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice.
Ahmad I; Masters GR; Schupsky JJ; Nguyen J; Ali S; Janoff AS; Mayhew E
Oncol Res; 1999; 11(6):273-80. PubMed ID: 10691029
[TBL] [Abstract][Full Text] [Related]
9. Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.
Thaker PH; Yazici S; Nilsson MB; Yokoi K; Tsan RZ; He J; Kim SJ; Fidler IJ; Sood AK
Clin Cancer Res; 2005 Jul; 11(13):4923-33. PubMed ID: 16000591
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
Cooper AL; Greenberg VL; Lancaster PS; van Nagell JR; Zimmer SG; Modesitt SC
Gynecol Oncol; 2007 Mar; 104(3):596-601. PubMed ID: 17049973
[TBL] [Abstract][Full Text] [Related]
11. A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity.
Banzato A; Bobisse S; Rondina M; Renier D; Bettella F; Esposito G; Quintieri L; Meléndez-Alafort L; Mazzi U; Zanovello P; Rosato A
Clin Cancer Res; 2008 Jun; 14(11):3598-606. PubMed ID: 18519794
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal adenovirus-mediated suicide gene therapy in combination with either topotecan or paclitaxel in nude mice with human ovarian cancer.
Kieback DG; Fischer DC; Engehausen DG; Sauerbrei W; Oehler MK; Tong XW; Aguilar-Cordova E
Cancer Gene Ther; 2002 May; 9(5):478-81. PubMed ID: 11961671
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity.
Vujaskovic Z; Feng QF; Rabbani ZN; Samulski TV; Anscher MS; Brizel DM
Exp Lung Res; 2002; 28(7):577-90. PubMed ID: 12396250
[TBL] [Abstract][Full Text] [Related]
14. Superior therapeutic profile of poly-L-glutamic acid-paclitaxel copolymer compared with taxol in xenogeneic compartmental models of human ovarian carcinoma.
Auzenne E; Donato NJ; Li C; Leroux E; Price RE; Farquhar D; Klostergaard J
Clin Cancer Res; 2002 Feb; 8(2):573-81. PubMed ID: 11839679
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
[TBL] [Abstract][Full Text] [Related]
16. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
17. Cytoprotective effects of amifostine and cysteamine on cultured normal and tumor cells treated with paclitaxel in terms of mitotic index and 3H-thymidine labeling index.
Ozcan Arican G
Cancer Chemother Pharmacol; 2005 Aug; 56(2):221-9. PubMed ID: 15838658
[TBL] [Abstract][Full Text] [Related]
18. Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice.
Silver DF; Hempling RE; Piver MS; Repasky EA
Gynecol Oncol; 2000 Jun; 77(3):377-82. PubMed ID: 10831345
[TBL] [Abstract][Full Text] [Related]
19. Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model.
Nukatsuka M; Fujioka A; Nakagawa F; Oshimo H; Kitazato K; Uchida J; Sugimoto Y; Nagayama S; Fukushima M
Int J Oncol; 2004 Dec; 25(6):1531-6. PubMed ID: 15547687
[TBL] [Abstract][Full Text] [Related]
20. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer.
Dai D; Holmes AM; Nguyen T; Davies S; Theele DP; Verschraegen C; Leslie KK
Cancer Res; 2005 Oct; 65(20):9517-24. PubMed ID: 16230417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
